Moleculin Biotech granted FDA Fast Track designation for WP1122

Moleculin Biotech announced that the U.S. FDA has granted Fast Track designation of WP1122 for the treatment of Glioblastoma Multiforme. The FDA’s Fast Track designation is intended to potentially facilitate the development and expedite the review of novel therapies to treat serious conditions for which there is unmet medical need. With the Fast Track designation, Moleculin is potentially eligible for more frequent regulatory meetings and communications with the FDA.